Brief: Zelluna ASA Activates First Clinical Site For Zima-101, Marking Entry Into Clinical Execution
06/05/2026 22:20
May 6 (Reuters) - Zelluna ASA ZLNA.OL: REG-ZELLUNA ASA ACTIVATES FIRST CLINICAL SITE FOR ZIMA-101, MARKING ENTRY INTO CLINICAL EXECUTION Source text: ID:nGNE568GkB Further company coverage: ZLNA.OL ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zelluna ASA
See all newsNorway's Zelluna ASA reports Q2 loss
Brief: Zelluna Reports Q2 Total Loss Of NOK 19.7 Million
Brief: Zelluna Says IDMC Recommends Recruitment Of Next Two Patients At First Dose Level
Brief: Zelluna Says First Patient Dosed With Zi-Ma4-1 In Zima-101 Phase 1 Trial
Brief: Zelluna Wins NOK 16 Mln Research Council Of Norway Grant